Altre lingue Femasys Inc.

Azioni

FEMY

US31447E1055

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 16/07/2024			Variaz. 5gg	Var. 1 gen.
1,2 ^USD	+7,14%		+9,09%	+23,08%

20/06	Femasys ottiene l'approvazione del marchio CE per quattro prodotti per la salute femminile; le azioni salgono di oltre il 14%.	MT
09/05	Femasys Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam	27/06
Femasys Secures CE Mark Approvals for Four Women's Health Products; Shares Up Over 14%	20/06
Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe	20/06
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative	20/05
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative	17/05
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council	16/05
Femasys Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Earnings Flash (FEMY) FEMASYS Reports Q1 Revenue $271,140	09/05
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update	09/05
Femasys Expands Commercial Management Team with Addition of Experienced New Hires	07/05
Femasys Expands Commercial Management Team with Addition of Experienced New Hires	07/05
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives	19/04
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives	18/04
Femasys Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update	28/03
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update	28/03
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed for the Treatment of Infertility	21/03
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape	21/03
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility	20/03
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility	20/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Femasys Inc.

Azioni

FEMY

US31447E1055

Altre lingue

Filtri